IL17A and Dorfman-Chanarin disease: The outcomes from our case report provide evidence supporting the inhibition of IL-17A and IL-17F for the treatment of DCS to address the underlying inflammatory mechanism, reduce symptoms, and help patients achieve control over their disease and improve their overall quality of life.